Binding affinity of synthetic cannabinoids to human serum albumin by high-performance affinity chromatography
DOI:
https://doi.org/10.48797/sl.2024.206Keywords:
PosterAbstract
Background: The use of new psychoactive substances (NPS) has been growing since the 2000’s, being the synthetic cannabinoids one of the groups reported on a larger scale. This group of NPS primarily interacts with the endocannabinoid system, which is involved in many physiological functions. Numerous reports of severe morbidity and mortality, linked to their consumption, have been documented [1,2]. Studies of toxicodynamics and toxicokinetics of synthetic cannabinoids are pivotal to increase the knowledge of this class of NPS. To our knowledge, studies of the interaction of synthetic cannabinoids with human serum albumin (HSA), the most abundant plasma protein, are still very limited [3]. Objective: This work aims the evaluation of binding affinity of a series of synthetic cannabinoids by high-performance affinity chromatography (HPAC). HPAC is a widely used and efficient technique to study intermolecular interactions between HSA and drugs [4,5]. Methods: The interaction of synthetic cannabinoids with HSA was investigated by HPAC by zonal elution experiments for measuring the retention times of each cannabinoid on an HSA column. Mixtures of potassium phosphate buffer (67 mM, pH 7.0) and acetonitrile were used as mobile phases in reversed elution mode. Results: The binding percentages (%b) values ranged from 94 to 99%. ADB-FUBINACA and AMB-FUBINACA (MMB-FUBINACA) showed the highest binding affinity both with a %b of 99%. Conclusions: The synthetic cannabinoids bounded to HSA with high affinity, which can interfere with drugs pharmacokinetics by increasing their free fraction in blood, as result of their eventual displacement from albumin or even by saturation of this protein. Zonal displacement chromatography studies are being conducted, using competitors with known specific binding sites on HSA, such as warfarin and (S)-ibuprofen, to shed light on the sites where the selected cannabinoids bind to the protein.
References
1. Roque-Bravo, R.; Silva, R.S.; Malheiro, R.F.; Carmo, H.; Carvalho, F.; da Silva, D.D.; Silva, J.P. Synthetic Cannabinoids: A Pharmacological and Toxicological Overview, Annu. Rev. Pharmacol. (2023), 63, 187–209.
2. Awuchi, C.; Aja M.P.; Mitaki N.B.; Morya, S.; Amagwula, I.O.; Echeta, C. K.; Igwe,V. S. New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions, J. Chem. (2023), 2023, 1.
3. Leboffe, L.; di Masi, A.; Trezza, V.; Polticelli, F.; Ascenzi, P. Human serum albumin: A modulator of cannabinoid drugs, IUBMB Life (2017) 69, 834.
4. Cardoso, T.; Almeida, A.S.; Remião, F.; Fernandes, C. Enantioresolution and Binding Affinity Studies on Human Serum Albumin: Recent Applications and Trends, Chemosensors (2021) 9, 304.
5. Almeida, A.S.; Almeida A. S.; Cardoso, T.; Cravo, S.; Tiritan M.E.; Remião, F., Fernandes, C. Binding studies of synthetic cathinones to human serum albumin by high-performance affinity chromatography, J. Chromatogr. B (2023) 1227, 123836.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Rita M. G. Santos, Sara Cravo, Fernando Remião, Carla Fernandes
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.
